Valuation: Unicycive Therapeutics, Inc.

Market Cap 139M 122M 113M 104M 197M 13.31B 200M 1.35B 528M 6.54B 522M 511M 22.58B P/E 2026 *
-3.68x
P/E 2027 * 1.01x
Enterprise Value 139M 122M 113M 104M 197M 13.31B 200M 1.35B 528M 6.54B 522M 511M 22.58B EV / Sales 2026 *
36.6x
EV / Sales 2027 * 0.48x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * 44.1%
1 day-3.36%
1 week-6.53%
Current month+6.82%
1 month-29.63%
3 months-24.32%
6 months-16.92%
Current year-13.17%
1 week 4.93
Extreme 4.93
5.71
1 month 3.93
Extreme 3.93
8.56
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
46.5
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
05-14Free

Chief Operating Officer

169,500 0.6716%
05-14Free

Chief Financial Officer

169,500 0.6716%
05-14Free

Director

126,300 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
-3.36%-6.53%+2.66%-59.60% 139M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-6.48%-3.09%+6.08%+415.45% 25.06B
-1.78%-3.76%-18.56%-17.45% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-1.21%+0.50%+22.44%+188.42% 14.2B
Average -2.08%-1.64%+43.84%+170.56% 24.17B
Weighted average by Cap. -1.95%-1.57%+47.50%+165.28%

Financials

2026 *2027 *
Net sales 3.8M 3.34M 3.09M 2.84M 5.38M 364M 5.48M 36.83M 14.45M 179M 14.29M 13.97M 618M 288M 253M 234M 216M 408M 27.6B 416M 2.79B 1.1B 13.55B 1.08B 1.06B 46.81B
Net income -40.34M -35.38M -32.77M -30.15M -57.03M -3.86B -58.14M -391M -153M -1.9B -151M -148M -6.55B 186M 163M 151M 139M 263M 17.82B 268M 1.8B 707M 8.75B 699M 684M 30.22B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
14/07/26 US$5.015 -3.74% 769,488
10/07/26 US$5.210 -0.95% 1,129,341
09/07/26 US$5.260 -3.13% 1,062,087
08/07/26 US$5.430 0.00% 1,385,273
07/07/26 US$5.430 +1.31% 2,345,161
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.210USD
Average target price
38.59USD
Spread / Average Target
+640.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock